Roger Song
Stock Analyst at Jefferies
(4.13)
# 499
Out of 5,090 analysts
50
Total ratings
46.34%
Success rate
19.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Maintains: Buy | $99 → $121 | $57.50 | +110.45% | 12 | Nov 26, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $45 | $30.94 | +45.44% | 1 | Nov 13, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $16 | $7.87 | +103.30% | 1 | Oct 10, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $485.21 | +16.24% | 1 | Sep 2, 2025 | |
| BMEA Biomea Fusion | Initiates: Buy | $5 | $1.17 | +325.79% | 1 | Aug 28, 2025 | |
| ATYR aTyr Pharma | Maintains: Buy | $9 → $17 | $0.83 | +1,941.06% | 2 | Aug 22, 2025 | |
| MBX MBX Biosciences | Assumes: Buy | $36 | $30.99 | +16.19% | 1 | Aug 15, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $54 | $41.10 | +31.39% | 3 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Buy | $31 → $6 | $10.50 | -42.83% | 2 | Jul 22, 2025 | |
| CVAC CureVac | Downgrades: Hold | $7 → $5 | $5.12 | -2.34% | 1 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.60 | +276.18% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $5.17 | +35.40% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $245 | $221.75 | +10.48% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $7.56 | +243.92% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $42 → $7 | $10.51 | -33.40% | 2 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $12.02 | +132.95% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $3.04 | +130.64% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $93.70 | -5.02% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $6.84 | +265.76% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $18.00 | +127.78% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $37.75 | -7.28% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $46.28 | +178.77% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2.5 → $8 | $4.09 | +95.60% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $107.05 | -9.38% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $38.86 | +183.07% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $5.31 | +559.13% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.54 | +484.42% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $8.85 | -9.55% | 2 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $210 | $8.81 | +2,283.65% | 1 | Sep 2, 2020 |
Nektar Therapeutics
Nov 26, 2025
Maintains: Buy
Price Target: $99 → $121
Current: $57.50
Upside: +110.45%
Oruka Therapeutics
Nov 13, 2025
Initiates: Buy
Price Target: $45
Current: $30.94
Upside: +45.44%
Gyre Therapeutics
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $7.87
Upside: +103.30%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $485.21
Upside: +16.24%
Biomea Fusion
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.17
Upside: +325.79%
aTyr Pharma
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.83
Upside: +1,941.06%
MBX Biosciences
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $30.99
Upside: +16.19%
Kiniksa Pharmaceuticals International,
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $41.10
Upside: +31.39%
Replimune Group
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $10.50
Upside: -42.83%
CureVac
Jun 13, 2025
Downgrades: Hold
Price Target: $7 → $5
Current: $5.12
Upside: -2.34%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $1.60
Upside: +276.18%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $5.17
Upside: +35.40%
Mar 5, 2025
Initiates: Buy
Price Target: $245
Current: $221.75
Upside: +10.48%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $7.56
Upside: +243.92%
Dec 9, 2024
Downgrades: Hold
Price Target: $42 → $7
Current: $10.51
Upside: -33.40%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $12.02
Upside: +132.95%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $3.04
Upside: +130.64%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $93.70
Upside: -5.02%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $6.84
Upside: +265.76%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $18.00
Upside: +127.78%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $37.75
Upside: -7.28%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $46.28
Upside: +178.77%
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $4.09
Upside: +95.60%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $107.05
Upside: -9.38%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $38.86
Upside: +183.07%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $5.31
Upside: +559.13%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $1.54
Upside: +484.42%
Dec 1, 2021
Initiates: Buy
Price Target: $8
Current: $8.85
Upside: -9.55%
Sep 2, 2020
Initiates: Buy
Price Target: $210
Current: $8.81
Upside: +2,283.65%